Emergency use – Brazil’s Health Regulator suspends Sputnik V analysis deadline

ANVISA adopted the measure due to the absence of documents essential to its analysis.

RIO DE JANEIRO, BRAZIL - The Brazilian Health Regulatory Agency (Anvisa) released a note this Saturday (March 27), advising the suspension of the deadlines for analysis of the request for emergency use of the Russian vaccine Sputnik V, made last week by União Química, the company responsible for the Russian immunization product, in Brazil.

"Due to the absence of documents considered important for the analysis, as provided by law, the deadlines were suspended until the company presents the information described as 'not presented' in the disclosed panel," says the agency.

According to Anvisa, the panel presents the percentage regarding . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?